Compounding pharmacies make customized medicines for individual patients, and under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy can compound from a bulk substance only if that substance has an official quality monograph, is a component of an FDA-approved drug, or has been formally added to an approved bulks list. BPC-157 qualifies on none of those counts, which is why the FDA placed it in Category 2 of its 503A bulk-substance review in September of 2023
ResearchGate - Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula: Discusses epithelization, collagenization, granulation tissue, and neovascularization
For most patients on standard one- to three-month cycles, this situation should not arise if ordering is timed appropriately to protocol length
How AOD 9604 Works at the Molecular Level The lipolytic activity of growth hormone has been understood since the 1960s
Nardacci, R